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SummAry
Benign tumours account for approximately 60-80% of parotid neoplasms and among these, Warthin’s tumour is the second most common 
benign neoplasm accounting for approximately 15% of all parotid epithelial tumours. The medical records of 100 consecutive patients with 
Warthin’s tumour of the parotid gland admitted for treatment at the Department of head and neck Surgery and otorhinolaryngology, hos-
pital A.C. Camargo, São Paulo, Brazil, between 1983 and 2011 were retrospectively analyzed. The surgical procedures included 104 (96%) 
subtotal parotidectomies and 4 (3.7%) total parotidectomies. one hundred and eight parotidectomies were performed in 100 patients with 
Warthin’s tumour. Postoperative complications occurred in 67 (62.3%) of surgical procedures, and facial nerve dysfunction was the most 
frequent complication, occurring in 51 of 108 surgeries (47.2%). The marginal mandibular branch of the facial nerve was affected in 46 of 
the 48 cases (95.8%) of facial nerve dysfunction. Frey’s syndrome was diagnosed in the late postoperative period in 19 patients (17.6%). 
We conclude that either superficial or total parotidectomy with preservation of facial nerve are the treatment of choice for Warthin’s tumour 
with no case of recurrence seen after long-term follow-up. Facial nerve dysfunction and Frey’s syndrome were the main complications 
associated with this surgery. Thus, if on one hand total parotidectomy is an appropriate radical resection of parotid parenchyma reducing, 
in theory, the risk of recurrence, on the other hand superficial parotidectomy is also a radical and efficient method with lower morbidity in 
terms of facial nerve dysfunction and Frey’s syndrome.
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riASSunTo
Le neoplasie benigne rappresentano circa il 60-80% dei tumori della ghiandola parotide e fra questi, il tumore di Warthin è il secondo isto-
tipo più frequente con una prevalenza del15% circa dei tumori epiteliali della parotide. Abbiamo analizzato retrospettivamente le cartelle 
cliniche di 100 pazienti affetti da tumore di Warthin trattati fra il 1983 e il 2011 presso il dipartimento di chirurgia della testa e del collo 
dell’ospedale di San Paolo “A.C. Camargo” (Brasile). Nei 100 pazienti analizzati furono effettuate 108 parotidectomie di cui 104 paro-
tidectomia subtotale (96%), e 4 parotidectomia totali (3,7%). Complicanze post operatorie si sono verificate nel 62,3% delle procedure 
chirurgiche e in particolare la disfunzione del nervo facciale fu la più frequentemente osservata (51/108 procedure effettuate – 47,2%). Una 
disfunzione del ramo marginalis mandibulae del nervo facciale eè stata riscontrata in 46 dei 48 casi (95,8%) con disfunzione del facciale. 
La sindrome di Frey’s fu riscontrata invece tardivamente in 19 pazienti (17,6% dei casi). Nella nostra casistica anche ad un follow-up a 
lungo termine non sono state apprezzate recidive di tumori di Warthin dopo parotidectomia esofacciale o totale con preservazione del ner-
vo facciale. La disfunzione del nervo facciale e la sindrome di Frey erano le principali complicanze osservate dopo la chirurgia. Benché la 
parotidectomia totale rappresenti l’approccio chirurgico più radicale i nostri dati dimostrano che la parotidectomia superficiale non solo 
consente di ottenere una buona radicalità chirurgica ma allo stesso tempo si associa ad una bassa moribidità in termini di disfunzione del 
nervo facciale e sindorme di Frey.  
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Introduction
Benign tumours account for approximately 60-80% of 
parotid neoplasms and comprise a heterogeneous group 
with distinct clinical and histological features and bio-
logical behaviour 1. Among these, Warthin’s tumour, also 
known as adenolymphoma or papillary lymphomatous 
cystadenoma, is the second most common benign neo-
plasm and accounts for approximately 15% of parotid 
epithelial tumours 2-4.
Warthin’s tumour is most common in male patients (4:1 
male:female ratio) during the sixth and seventh decades 
of life  5. Unlike other benign neoplasms of the salivary 
glands, this tumour has a tendency towards bilateral in-
volvement, and approximately 90% of lesions occur in the 
superficial lobe of the parotid gland 6. Histologically, the 
tumour has an oncocytic epithelial component forming 
uniform rows of cells surrounded by cystic spaces associ-
ated with a lymphoid stroma often showing the presence 
of germinal centres (Figs.  1,  2)  7. Treatment consists of 
partial, subtotal or total parotidectomy with preservation 
of the facial nerve 8. Malignant transformation is described 
in only 0.1% of cases, and usually arises in the epithelial 
component of the lymphoid tissue tumour 9. The incidence 
of recurrence after surgical treatment is extremely rare 5.
The aim of this study is to describe the outcomes of pa-
tients with Warthin’s tumour of the parotid gland consid-
ering clinical and demographic characteristics, type of 
surgery, complications and the incidence of recurrence.
Patients and methods
The medical records of 100 consecutive patients with 
Warthin’s tumour of the parotid gland admitted for treat-
ment at the Department of Head and Neck Surgery and 
Otorhinolaryngology, Hospital “A.C. Camargo”, São 
Paulo, Brazil, between 1983 and 2011 were retrospec-
tively analyzed. One hundred and thirteen tumours were 
diagnosed in 100 patients with a median age of 58 years 
(range 32-84 years). There were 72 males and 28 females. 
Of these, 75 patients (75%) were Caucasian. Tobacco use 
was reported at diagnosis by 72 patients and 11 reported 
a previous history of smoking. Four patients had bilateral 
synchronous tumours and 9 had bilateral metachronous 
tumours. The treatment employed was surgery in all cases.
The surgeries were performed by several surgeons from 
the same department, mostly residents directly supervised 
by specialists in head and neck surgery. The surgical pro-
cedures included 104 (96%) subtotal/superficial parot-
idectomies, defined by the resection of tumours located 
in the superficial portion of the gland (above the nerve) 
and 4 (3.7%) total parotidectomies, indicated for those tu-
mours located in the deep lobe of gland. The facial nerve 
was identified and preserved in all cases. In three of the 
four patients with bilateral synchronous tumours, surgery 
was performed only on the side where the tumour was 
larger. Otherwise, in 9 patients with metachronous bilat-
eral tumours, contralateral parotidectomy was performed 
in 7 cases. All eight contralateral parotidectiomies in pa-
tients with bilateral tumours were performed at different 
times. In five patients with bilateral tumours, the second 
side was not operated because of patient refusal or for 
clinical reasons (small tumours and few symptoms).
Routinely, the facial nerve trunk is identified before making 
the identification and dissection of its branches. No devices 
were used to identify the nerve in primary surgeries. In two 
patients, the mandibular branch of facial nerve was sacri-
ficed because of reported tumour involvement, and these 
cases were not included in the analysis of postoperative 
nerve dysfunction. Rotation of sternocleidomastoid muscle 
flap (SMF) was performed in the last 10 years to fill the 
parotid bed after resection and to reduce the incidence of 
Frey’s syndrome. The type of drain used varied during the 
study period. The Penrose drains that were originally used 
were replaced in 1994 by vacuum drainage Hemovac (Por-
Fig. 1. Histological section stained with HE with 40x magnification, showing 
the interface between the salivary gland and the tumor.
Fig. 2. Histological section stained with HE with 40x magnification, dem-
onstrating the neoplasm characterized by cystic and solid areas, cells with 
abundant granular and eosinophilic cytoplasm with central nuclei. The stro-
ma is rich in lymphocytes.
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tovac), and in the last decade we have used silicone drains 
(Jackson-Pratt and Blake) to facilitate postoperative care 
and allow early hospital discharge.
SPSS 17.0 was used for statistical analysis. The asso-
ciation between variables with the occurrence of com-
plications was evaluated by chi-square or Fisher’s exact 
test, as appropriate. The Mann-Whitney test was used 
to evaluate the difference between the mean length of 
hospitalization. A p value < 0.05 was considered statisti-
cally significant.
Results
One hundred and eight parotidectomies were performed 
in 100 patients with Warthin’s tumour. The time of hospi-
talization varied from 1 to 19 days (median, 2 days). Post-
operative complications occurred in 67 (62.3%) surgical 
procedures, and facial nerve dysfunction was the most 
frequent complication, followed by other less frequent 
complications such as seroma and infection (Table  I). 
There was no total facial nerve dysfunction or postop-
erative mortality. The mean and median days of hospi-
talization between the patients who did or did not have 
postoperative complications were similar and not statisti-
cally different. Similarly, the incidence of postoperative 
complications did not show statistically significant cor-
relation with gender, age, smoking and alcohol, type of 
parotidectomy, nodule size and use of the sternocleido-
mastoid muscle flap.
Postoperative facial nerve dysfunction occurred in 51 of 
108 surgeries (47.2%) (Table I). In 43 cases (84.3%), dys-
function was transitory with recovery of function occur-
ring in a period ranging from 1 to 19 months (median, 4 
months). Unfortunately, in eight cases there was no de-
tailed report in the clinical chart regarding recovery from 
facial mobility. The marginal mandibular branch of the 
facial nerve was affected in 46 of the 49 cases (93.8%). 
Six cases (12.2%) had dysfunction of other associated 
branches. Only one patient had postoperative dysfunction 
of all branches of the facial nerve.
Seroma and haematoma were found in 2 of 108 (1.9%) 
procedures. All were treated conservatively with aspira-
tion. Wound infection was observed in 10 of 108 (9.2%) 
procedures. There was no statistically significant correla-
tion with the incidence of wound infection and the type of 
drain used. Two cases of fistula occurred.
Frey’s syndrome was diagnosed in the late postoperative 
period in 19 patients (17.6%) (Table II). There were no re-
ports of bilateral Frey’s syndrome in patients with surgery 
on both sides. Frey’s syndrome occurred less frequently in 
patients who underwent rotation of the sternocleidomas-
toid muscle flap (SMF) to fill the parotidectomy field (10 
of 67; 14.9%) compared with cases that did not undergo 
flap reconstruction (9 of 41; 22%), but this difference was 
not statistically significant.
Discussion
Warthin’s tumour is a benign neoplasm, first described by 
Aldred Warthin in 1929, which occurs predominantly in 
the parotid gland and represents approximately 15% of 
parotid tumours 5 9. Fewer than 10% of cases occur out-
side this gland 5. Furthermore, bilateralism is described in 
5-15% of cases and multifocality in 6-20% 9-12. In our se-
ries, we studied only tumours of the parotid gland, and bi-
lateral Warthin’s tumours were observed in 13 (13%) pa-
tients, (4 synchronous cases and 9 metachronous cases). 
Although the occurrence of bilateral Warthin’s tumour is 
relatively common in this group of patients, the presence 
of a bilateral synchronic tumour is rare 11-14.
The origin of Warthin’s tumour is unknown and its clas-
sification as cancer is controversal  15  16. Surgery is the 
main mode of therapy used and is associated with a low 
recurrence rate 15. Several authors have correlated recur-
rence rate with the extent of surgery, which ranges from 
0-13% 5 11 17. In our study, superficial parotidectomy with 
facial nerve preservation was used in 97% of cases, and 
there were no cases of recurrence after a median follow-
up of 31 months. Although superficial parotidectomy is 
the treatment of choice for patients with benign tumours 
of the parotid gland, it is associated with both early and 
late complications 18 19.
The main complications associated with surgery of the 
parotid gland are facial nerve dysfunction and Frey’s syn-
drome. Postoperative dysfunction of the facial nerve may 
be total or partial (some branches), and transient or perma-
Table II. Incidence of Frey’s Syndrome.
Frey’s Syndrome
No Yes
Parotidectomy Partial 78 19
Total 4 0
SMF No 21 9
Yes 56 10
Follow-up Min 6 m
Max 20 y
Mean 4.13 y
Median 2 y
SMF: sternocleidomastoid muscle flap; m: month; y: years.
Table I. Complications in 108 parotidectomies for Warthin’s tumour.
Complication n %
Number* 44 40.7
Facial nerve dysfunction 51 47.2
Infection 10 9.2
Seroma 2 0.9
Haematoma 2 0.9
Fistula 2 0.9
* Some patients had more than one complication.
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nent 20 21. On the other hand, Frey’s syndrome is detected 
later, may be symptomatic or asymptomatic and its diagno-
sis is performed with the Minor test that is based on appli-
cation of a solution containing 1.5 g of iodine, 10 g of cas-
tor oil and 88.5 g of absolute alcohol that must be applied to 
the skin of the parotid region. After drying, starch powder 
should be applied, which together with local sweating, will 
produce a blue iodine-starch reaction 22 23.
In the literature, the incidence of transient dysfunction 
of the facial nerve has been reported in 10-68% of cases, 
while permanent dysfunction occurs in 0-19% 20 24. In our 
series, the incidence of postoperative dysfunction of facial 
nerve was 47.2%. The marginal mandibular branch was 
the most affected with 90% of cases of nerve dysfunction, 
although total dysfunction (all branches) was detected in 
only 1 patient. Classification regarding the degree of fa-
cial nerve dysfunction could not be done since this was 
a retrospective study, and this data was not evaluated in 
most cases.
Dysfunction of the marginal mandibular branch is a major 
problem and has been reported in 48-59% of cases in the 
literature 21 25. Several factors have been described to be 
associated with an increased incidence of postoperative 
dysfunction of the facial nerve after parotidectomy 26. Yu-
an, in 2009, studied 626 patients undergoing surgery for 
benign disease of the parotid and found that the factors as-
sociated with increased postoperative dysfunction of the 
facial nerve were the extent of parotidectomy and diabetes 
mellitus 21. Similarly, Koch in 2010 observed facial nerve 
dysfunction in 32.7% of cases, and the main factor was 
the extent of surgery 19. In another study of 162 patients 
who underwent parotidectomy for benign disease, the 
presence of facial nerve dysfunction was observed in 40% 
of cases. In this study, the presence of inflammation and 
parotidectomy for Warthin’s tumour were the factors that 
were most relevant to dysfunction 27. In our study, there 
were no factors that significantly correlated with postop-
erative dysfunction of the facial nerve.
Frey’s syndrome has been described as a main compli-
cation related to surgery of the parotid gland. The inci-
dence of this syndrome varies widely according to the 
diagnostic investigation. It is reported spontaneously 
for about 10% of patients, but when questioned active-
ly about the existence of gustatory sweating, approxi-
mately 30-40% of patients report the presence of such 
symptoms. Moreover, when under diagnostic investiga-
tion, Frey’s syndrome is seen in up to 95% of patients 
undergoing parotidectomy 23. In our study, the diagnosis 
of Frey’s syndrome was made based on spontaneously 
clinical complaints of the patient or after being ques-
tioned by the attending physician about symptoms dur-
ing follow-up, and was seen in 17.6% of patients. This 
occurred more often in patients in whom a SMF was not 
used to fill the parotid space (22% vs. 14.9%). However, 
this difference was not statistically significant. When 
symptomatic, Frey’s syndrome was treated with botu-
linum toxin injection in the most severe cases, and by 
applying deodorants or antiperspirants in milder cases. 
Queiroz Filho, in 2004, studied the occurrence of Frey’s 
syndrome in 2 groups of patients according to the pres-
ence or absence of SMF and found that 47.4% (9/19) of 
patients in the group who did not receive the flap had 
complaints of gustatory sweating, and in 36.8% (7/12) 
of patients the Minor test was positive. Otherwise, in the 
group that received the flap, complaints or a positive test 
for Minor were not found  28. In a systematic literature 
review, Sanabria concluded that there is not sufficient 
clinical evidence to determine that the use of SMF in 
preventing Frey’s syndrome is an effective procedure in 
preventing Frey’s syndrome 29.
We conclude that either superficial or total parotidecto-
my with preservation of the facial nerve are the preferred 
treatments for Warthin’s tumour with no case of tumour 
recurrence seen during long-term follow-up. Facial nerve 
dysfunction and Frey’s syndrome were the main com-
plications associated with this surgery. Thus, if in one 
hand, total parotidectomy is an appropriate radical resec-
tion of parotid parenchyma reducing, in theory, the risk 
of recurrence, on the other superficial parotidectomy is 
also a radical and efficient method with low morbidity in 
terms of facial nerve dysfunction and Frey’s syndrome. 
Currently, resections such as those of the lower extremity 
of the superficial pole of parotid should not be ruled out, 
as they can be performed safely in lower tumours, allow-
ing lower manipulation of cranial branches of the facial 
nerve with less morbidity. However, further prospective 
and randomized studies are needed to reach a more defini-
tive conclusion.
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